Off the wire
• News Analyis: Escalating violence in Nepal's Terai region poses threats to journalists  • China names new special envoy for Afghanistan affairs  • 2nd LD Writethru-China Focus: China's legislature ratifies AIIB agreement  • Benzema arrested over sex-blackmail tape  • Roundup: Singapore stocks end up 1.36 pct  • China Exclusive: Scientists decode giant panda language  • Chinese commercial banks' bad loan rate continues to rise in Q3  • China to launch road etiquette education campaign  • Former Espanyol president explains decision to sell club to Chinese  • Port executive sacked over Tianjin blasts  
You are here: 　 Home

Denmark's Novo Nordisk to invest 300 mln USD in new facility

Xinhua, November 4, 2015 Adjust font size:

Danish pharmaceutical company Novo Nordisk will invest 2.1 billion Danish kroner (309 million U.S. dollars) in a new insulin filling facility in Denmark, the company said Wednesday in a statement.

The 10,300-square-meter facility will be located in Hilleroed, north of Copenhagen, and produce medicines for the treatment of diabetes and obesity. It is expected to be operational in 2019 and will create 450 new jobs in Hilleroed, where Novo Nordisk already employs 1,900 people.

"The investment in Hilleroed underscores our long-term ambition to create and maintain jobs in Denmark," said Henrik Wulff, Novo Nordisk's executive vice president and head of Product Supply, noting that this year alone the company has created 1,000 new jobs in Denmark.

A groundbreaking ceremony marking the start of construction of the new facility will be held later on Wednesday. Endi